Estée Lauder, Serpin Pharma partner to advance skin care innovation
USA – The Estée Lauder Companies has partnered with Serpin Pharma, a clinical-stage pharmaceutical company, to explore the potential applications of its anti-inflammatory research in cosmetics.
This collaboration aims to revolutionize skin care by delivering longevity benefits to consumers worldwide.
Serpin Pharma has discovered a crucial segment of the SERPIN (Serine Protease Inhibitor) protein superfamily that boosts the body’s natural ability to repair cells affected by inflammation.
The two companies are exploring how this technology can be utilized in the cosmetics industry to effectively reduce visible signs of aging and skin irritation.
Carl Haney, Executive Vice President of Global Innovation and Research and Development (R&D) at ELC, said, “This novel technology will advance our transformative innovation agenda by pushing the boundaries of breakthrough scientific discovery.”
“In partnership with Serpin Pharma, we’re exploring powerful new biological pathways and cutting-edge biotech ingredients to rapidly mitigate visible skin irritation and sensitivity for our prestige beauty consumers worldwide.”
According to Serpin Pharma, their proprietary biotech technology has effectively reduced harmful inflammation and strengthened cell resilience.
Cohava Gelber, PhD, MBA, Founder, Executive Chairperson and CEO, Serpin Pharma, said, “We’re taking a novel approach by tapping into the body’s innate mechanism for resolving inflammation.¨
¨We are proud to partner with ELC to explore how our powerful biotechnology can be applied to cosmetics and skin care.”
This collaboration further strengthens ELC’s commitment to pioneering product innovation, enabling fast-to-market, trend-driven solutions across high-demand subcategories.
Estée Lauder Companies recently reported its fiscal 2025 second-quarter results, with net sales of $4.0 billion, a decrease of 6% from the same period last year.
Despite the decline in sales, the company’s gross margin expanded by 310 basis points to 76.1%, primarily driven by benefits from its Profit Recovery and Growth Plan (PRGP).
However, the operating margin declined to 14.5% from 13.4% in the prior year, reflecting $861 million in goodwill and other intangible asset impairments and $181 million in accelerated productivity program spending.
To restore sustainable sales growth and strengthen profitability, the company launched a new strategic vision, Beauty Reimagined, to boost its sales.
The initiative aims to put the consumer first and rapidly expand ELC’s portfolio presence in consumer-preferred, high-growth channels, markets, media, and price tiers to participate in key growth opportunities in prestige beauty.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
